Sitavia 100 mg Tablets (Sitagliptin Phosphate)
Sitagliptin Phosphate 124.08mg
Tablet · Prescription medication
Yu Yu Pharmaceutical Co., Ltd.
MFDS item code 201503174 · Approved 2015.05.27
This product's status changed to Expired on 2025.05.27. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used as an adjunct to diet and exercise in managing blood sugar levels in patients with type 2 diabetes. It may be used alone at the start of treatment and can be combined with metformin in cases where previous diabetes treatment has not been effective. If blood sugar is not adequately controlled with mono-therapy using sulfonylureas, metformin, thiazolidinediones, or insulin, this medication can also be added. It is effective in improving blood sugar control in type 2 diabetes patients when employed in various stages of treatment.
This drug is administered at 100 mg once daily as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This drug may be taken without regard to meals. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, section 5. General Precautions). Because dose adjustment according to renal function is required, assessment of renal function is recommended before and periodically during treatment with this drug. 1. No dose adjustment is required in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dose adjustment is required in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45mL/min/1.73 m2 and < 60mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30mL/min/1.73 m2 and < 45mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15mL/min/1.73 m2 and < 30mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This drug may be administered regardless of the timing of dialysis.
This medication may cause severe allergic reactions, so if symptoms such as rash, difficulty breathing, or swelling of the face or neck appear after administration, use should be stopped immediately and a physician consulted. During treatment, if symptoms of acute pancreatitis such as severe abdominal pain, vomiting, or fever occur, stop taking the medication and inform medical personnel immediately. Patients with type 1 diabetes or diabetic ketoacidosis should not use this medication, nor should individuals allergic to this medication or its components. Patients with impaired kidney function need to be cautious with this medication’s dosage, and routine kidney function tests before and during treatment are important. Hypoglycemia may occur when this medication is used alone or in combination with other diabetes medications, particularly when used with insulin or sulfonylureas. Rare side effects such as severe joint pain or blistering conditions similar to pemphigus have been reported, so if such symptoms occur, notify a doctor immediately. The use of this medication is not recommended for pregnant or breastfeeding women, and safety in pediatric patients under 18 years old has not been established. In case of overdose, general emergency treatments such as gastrointestinal decontamination may be needed, and this medication can be partially removed by hemodialysis. This medication does not significantly impact cardiovascular safety, but regular health check-ups and consultations with healthcare professionals are necessary during administration.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a sealed container to prevent air ingress and is best kept at room temperature between 1°C and 30°C. This will help maintain the drug's efficacy and prevent degradation.
Beige, convex, round film-coated tablet on both sides
30 tablets (10 tablets/PTPX3)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Phosphate 124.08mg
Tablet · Prescription medication
Yu Yu Pharmaceutical Co., Ltd.

Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication
Jongkeundang Co., Ltd.

Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Jongkundang Co., Ltd.

Sitagliptin Phosphate Hydrate 32.13mg
Tablet · Prescription medication
Jong Kundang Co., Ltd.
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Vivozon Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 32.125mg
Tablet · Prescription medication
Sinpoong Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.